Dr. Tagawa on IMMU-132 Trial Updates in Urothelial Cancer

Scott T. Tagawa, MD
Published: Thursday, Feb 16, 2017



Scott T. Tagawa, MD, Weill Cornell Medicine/New York-Presbyterian, discusses updated results from the IMMU-132 trial in metastatic urothelial cancer (mUC).

In the study, patients who were pretreated with platinum-containing chemotherapy received IMMU-132, an anti-Trop-2-SN-38 antibody-drug conjugate.

Of 44 patients, 36 are evaluable for response—which met the primary endpoint. At the time of these results, the response rate is above 30% and durable.
 

<<< View more from the 2017 Genitourinary Cancers Symposium



Scott T. Tagawa, MD, Weill Cornell Medicine/New York-Presbyterian, discusses updated results from the IMMU-132 trial in metastatic urothelial cancer (mUC).

In the study, patients who were pretreated with platinum-containing chemotherapy received IMMU-132, an anti-Trop-2-SN-38 antibody-drug conjugate.

Of 44 patients, 36 are evaluable for response—which met the primary endpoint. At the time of these results, the response rate is above 30% and durable.
 

<<< View more from the 2017 Genitourinary Cancers Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x